Cargando…

Analysis of the Immunogenicity from Abatacept‐Treated Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials

OBJECTIVE: The goal of this article is to present the analysis of anti‐abatacept antibody data from children with polyarticular‐course juvenile idiopathic arthritis (pJIA), treated with abatacept. The data are from 395 participants with pJIA from two abatacept registrational trials. METHODS: We anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mora, Johanna R., Wong, Robert, Shaikh, Mehmooda, Askelson, Margarita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843768/ https://www.ncbi.nlm.nih.gov/pubmed/34792858 http://dx.doi.org/10.1002/acr2.11375

Ejemplares similares

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
por: Hara, Ryoki, et al.
Publicado: (2019)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Gandhi, Yash, et al.
Publicado: (2021)

Safety and Effectiveness of Tofacitinib in Treating Polyarticular Course Juvenile Idiopathic Arthritis
por: Jones, Nicholas T, et al.
Publicado: (2023)

Advances in the treatment of polyarticular juvenile idiopathic arthritis
por: Webb, Kate, et al.
Publicado: (2015)

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept
por: Brunner, Hermine I., et al.
Publicado: (2020)

Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches
por: Oberle, Edward J, et al.
Publicado: (2014)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Radiological cervical spine involvement in polyarticular idiopathic juvenile arthritis
por: Wipff, J, et al.
Publicado: (2011)

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
por: Bakry, Reima, et al.
Publicado: (2022)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
por: McIntosh, Sydney Moore, et al.
Publicado: (2023)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison
por: Sawyer, L, et al.
Publicado: (2013)

Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis
por: Marangoni, Roberta Gonçalves, et al.
Publicado: (2011)

Slow speed resistance exercise training in children with polyarticular juvenile idiopathic arthritis
por: Sule, Sangeeta D, et al.
Publicado: (2019)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Study of the shared gene signatures of polyarticular juvenile idiopathic arthritis and autoimmune uveitis
por: Zheng, Jie, et al.
Publicado: (2023)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

PAIN PERCEPTION AND PAIN COPING MECHANISMS IN CHILDREN AND ADOLESCENTS WITH JUVENILE FIBROMYALGIA AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
por: Fraga, Melissa Mariti, et al.
Publicado: (2018)

Whole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis
por: Jiang, Kaiyu, et al.
Publicado: (2016)

Prior to extension, Transcriptomes of fibroblast-like Synoviocytes from extended and Polyarticular juvenile idiopathic arthritis are indistinguishable
por: Brescia, AnneMarie C., et al.
Publicado: (2018)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review
por: Chaplin, Hema, et al.
Publicado: (2021)

Childhood-Onset COPA Syndrome Recognized Retrospectively in the Context of Polyarticular Juvenile Idiopathic Arthritis and Rheumatoid Arthritis
por: Nikolic, Roko P. A., et al.
Publicado: (2023)

PReS-FINAL-2160: Intestinal microbiome in polyarticular juvenile idiopathic arthritis: a pilot study
por: Hissink Muller, PC, et al.
Publicado: (2013)

Polyarticular juvenile idiopathic arthritis (pJIA): clinical and serologic predictors of inactive disease (ID)
por: Meiorin, Silvia
Publicado: (2014)

A Novel Method for Pathway Identification Based on Attractor and Crosstalk in Polyarticular Juvenile Idiopathic Arthritis
por: Wang, Yuanji, et al.
Publicado: (2016)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis
por: Soulsby, William Daniel, et al.
Publicado: (2022)

α2-fraction and haptoglobin as biomarkers for disease activity in oligo- and polyarticular juvenile idiopathic arthritis
por: Zeller, Ludwig, et al.
Publicado: (2022)

Identification of key biomarkers in RF-negative polyarticular and oligoarticular juvenile idiopathic arthritis by bioinformatic analysis
por: Liu, Yun, et al.
Publicado: (2023)

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2015)

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy
por: Goldzweig, Ofra, et al.
Publicado: (2011)

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2018)

Single nucleotide polymorphism of NLRP3 (Q705K) In juvenile spondyloarthritis and oligo/ polyarticular juvenile idiopathic arthritis
por: Perica, Marija, et al.
Publicado: (2014)

Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
por: Klein, Ariane, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ml1scb0qsbk71jjvpej820ue1p